Ella is owned by Lab Hra Pharma.

Ella contains Ulipristal Acetate.

Ella has a total of 8 drug patents out of which 0 drug patents have expired.

Ella was authorised for market use on 13 August, 2010.

Ella is available in tablet;oral dosage forms.

Ella can be used as a method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse, ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food, method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99, method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse, a method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse.

The generics of Ella are possible to be released after 12 June, 2030.